Danish biotech Bavarian Nordic said on Wednesday it is doing “everything possible” to meet high demand for its monkeypox vaccine around the world, while maintaining its business outlook for the year.
Bavarian is the only producer of an approved monkeypox vaccine, but the vaccine is in short supply and several countries are stretching available doses, with unknown results, to make the most of existing supplies.
“We are doing everything we can to meet initial global demand for our monkeypox vaccine and are working diligently to further expand our manufacturing capacity through additional scale-up activities and partnerships,” CEO Paul Chaplin said in a statement. .
Bavarian said sales of its monkeypox vaccine — called Jynneos, Imvanex or Imvamune, depending on the country — reached 117 million Danish kroner ($15.65 million) in the second quarter.